- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
News 145 results
In the News · Source: Le Monde du Droit
April 28, 2021
Laurent Bensaid, Julien Vicariot, Elisa Lirot, Aurélia de Viry and Geneviève Michaux advise Creadev on its investment in Alira Health
In the News · Source: The Pharma Letter
In the News · Source: Medtech Insight
April 23, 2021
Steve Niedelman explains the steps that companies should follow to prepare for a regulatory meeting with the FDA
In the News · Source: Pink Sheet
April 22, 2021
Geneviève Michaux discusses the EU Clinical Trial Regulation’s process for registering and evaluating clinical trials
Recognition
April 20, 2021
Law360 Selects Nine from King & Spalding to Serve on 2021 Editorial Advisory Boards
In the News · Source: Pink Sheet
April 12, 2021
Eva Temkin comments on Patrizia Cavazzoni being named the permanent director of the Center for Drug Evaluation and Research
In the News · Source: Pink Sheet
In the News · Source: InsideHealthPolicy
April 8, 2021
The firm forms an industry group to challenge white bagging policies
In the News · Source: The Center for Biosimilars
March 30, 2021
Eva Temkin discusses the chances that biosimilars will be developed for orphan drugs
In the News · Source: Politico, Bloomberg Law, The Daily Docket, IP Magazine, Law.com, Law360, Bloomberg Law, Generics Bulletin, Pharmalife, Endpoints News and The Washington Post
Press Release
March 29, 2021
FDA Acting Policy Director for Office of Therapeutic Biologics and Biosimilars Joins King & Spalding
In the News · Source: The Center for Biosimilars
March 29, 2021
Eva Temkin addresses the changing regulatory landscape and public perceptions of biosimilars